dr. wierda on ibrutinib plus venetoclax in cll
Published 7 years ago • 957 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
3:59
the critical role of sirt3 in lymphomagenesis
-
3:33
investigating the safety and efficacy of re-treating cll patients with venetoclax-based regimens
-
1:37
cryoglobulinaemic vasculitis related to hepatitis c: dr. david liew
-
1:22
dr. schiller on venetoclax and glasdegib in aml
-
2:57
dr william wierda discusses cll phase 3 trial data as presented at ash
-
2:40
lotis-2: r/r dlbcl patient characteristics impact dor to loncastuximab tesirine
-
1:45
share your story: lisa schiller - chla
-
2:31
shorter time from leukapheresis to infusion of axi-cel shows better cr and os in r/r lbcl
-
2:22
selinexor and rice chemotherapy in relapsed/refractory dlbcl
-
1:13
dr. wierda discusses the need for newer therapies in cll
-
1:42
dr. wierda on combination regimens with venetoclax in cll
-
1:34
tls in patients with cll treated with venetoclax
-
0:58
explaining what is cryo-laser and cryo-sclerotherapy (clacs)
-
1:15
the current role of acalabrutinib in the treatment of cll
-
1:51
rationale of omniverse: oral azacitidine venetoclax in patients with r/r or newly diagnosed aml
-
1:16
lotis-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with dlbcl
-
6:03
quazar aml-001: oral azacitidine as maintenance therapy in aml
-
1:24
dr. lee akst
-
3:14
rationale-301: elderly subgroup analysis of tislelizumab in hcc